2026paź
DXCM Oct 2026 · Sell
DexCom Inc. (NASDAQ: DXCM) is assigned a Sell rating with a composite Fair value of $58.97 against a market price of $85.36, representing an implied downside of -30.9% and a 44.8% price premium to intrinsic value. While DexCom retains a wide economic moat in continuous glucose monitoring (CGM) through software algorithms and automated insulin delivery pump integrations, the stock's forward P/E multiple of 28.25x overly discounts operational execution and leaves investors exposed to significant multiple contraction.Latest published research · analyzed 2026-10-04 · current · sources aging